The discontinuation of the Phase 3 LIMT-2 study due to safety concerns could negatively impact investor confidence in Eiger BioPharmaceuticals, leading to a decrease in its stock price. The company's decision to focus on avexitide could potentially offset some of this negative impact, but it's unclear at this time how successful this strategy will be.